Companies Deal Date Announced
Alnylam Pharmaceuticals and Merck Alnylam is developing siRNAs against a number of Merck targets. Under the deal, Merck may develop the drug candidates alone or in partnership with Alnylam.
Sept. 9, 2003 -
RNAi News, 9/12/2003
Sirna Therapeutics and Eli Lilly Sirna generated modified siRNAs against Lilly-selected oncology targets. Lilly had the option of licensing promising candidates under the now-ended deal.
Jan. 27, 2004 -
RNAi News, 1/30/2004
Alnylam Pharmaceuticals and Merck The companies partnered on the development of RNAi-based drugs for ocular diseases. This arrangement was later dropped and the companies' alliances were consolidated.
June 30, 2004 -
RNAi News, 7/2/2004
Alnylam Pharmaceuticals and Medtronic Alnylam is developing RNAi-based drugs for various diseases, which will be delivered using Medtronic devices to specific locations in the nervous system.
Feb. 9, 2005 -
RNAi News, 2/11/2005
Alnylam Pharmaceuticals and Novartis The companies are collaborating on developing RNAi drugs against Novartis-selected targets in multiple disease areas. As part of the deal, Novartis paid Alnylam an upfront fee and bought a 19.9-percent stake in the RNAi firm.
Sept. 7, 2005 -
RNAi News, 9/9/2005
Sirna Therapeutics and GlaxoSmithKline Sirna is developing optimized and formulated siRNAs against targets specified by the GlaxoSmithKline, which will handle all development and commercialization activities for the drugs. In exchange, Sirna received $12 million upfront and stands to receive up to $700 million in milestones and royalties.
April 3, 2006 -
RNAi News, 4/6/2006
Sirna Therapeutics and Allergan Allergan acquired the rights to Sirna's phase I age-related macular degeneration drug Sirna-027 for $5 million upfront, up to $245 million in milestones, and royalties.
Sept. 29, 2005 -
RNAi News, 10/7/2005
Dharmacon and Alcon Dharmacon is developing siRNAs against ocular disease gene targets, with Alcon selecting the most promising candidates for development.
Oct. 19, 2005 -
RNAi News, 10/21/2005
Dharmacon and Abbott The companies are working together to discover siRNA-based therapeutics in multiple indications including cancer.
July 6, 2006 -
RNAi News, 7/6/2006
Alnylam Pharmaceuticals and Biogen Idec Alnylam is helping Biogen Idec develop an RNAi-based treatment for progressive multifocal leukoencephalopathy, an opportunistic viral infection of the brain that has been associated with Biogen Idec's multiple sclerosis drug Tysabri.
Sept. 20, 2006 -
RNAi News, 9/21/2006
Quark Biotech and Pfizer Pfizer acquired from Quark RTP-801i, an siRNA-based molecule that silences the age-related macular degeneration target RTP-801. Sept. 26, 2006 -
RNAi News, 9/28/2006
Sirna Therapeutics and Merck Merck agreed to buy Sirna for $1.1 billion in cash, or $13 per share. The acquisition is expected to close in the first quarter of 2007.
Oct. 30, 2006 -
RNAi News, 11/2/2006